SCHEMBL20535306

SCHEMBL20535306

[N-]=[N+]=NC(=Cc1ccc(Cl)cc1Oc1cc(Cl)ccc1Cl)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 4/20 0.40
▸ PLA2G1B P04054 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ATG4B Q9Y4P1 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ TTR P02766 2/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ GPBAR1 Q8TDU6 2/20 0.32
▸ TP53 P04637 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535305 1.00 RHEB (0.40) RHEBPLA2G1BMAPTATG4BMRGPRX4
SCHEMBL23709904 0.87 RHEB (0.35) RHEBPLA2G1BMAPTATG4BTTR
SCHEMBL18990057 0.83 ALDH1A1 (0.38) ALDH1A1TP53POLBMEN1CYP1A2
SCHEMBL20535994 0.78 GRIK1 (0.34) MAPTALDH1A1KDM4EMEN1CYP1A2
SCHEMBL29063087 0.78 GPR183 (0.34) MAPTALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL20535997 0.78 GRIK1 (0.34) MAPTALDH1A1KDM4EMEN1CYP1A2
SCHEMBL20535418 0.77 RHEB (0.47) RHEBALDH1A1KDM4E
SCHEMBL20535416 0.77 RHEB (0.47) RHEBALDH1A1KDM4E
SCHEMBL20535973 0.77 HTR2A (0.41) CYP3A4CYP2D6CYP2C19
SCHEMBL20535972 0.77 HTR2A (0.41) CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885PLA2G1B 143/4885MAPT 4119/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885PLA2G1B 385/4885MAPT 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback